Biotech · Public company · San Francisco, CA, US
GT Biopharma, Inc.
Ticker GTBP · SEC CIK 0000109657
Track this companyFree. Adds GT Biopharma, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials21 recruiting or active
Pipeline programs2From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline2
- GTB-3550 TriKE® Phase IPhase 2 · High-risk Myelodysplastic SyndromesClinicalTrials.gov · fetched Nov 12, 2026
- GTB-3550 TriKE® Phase IIPhase 2 · High-risk Myelodysplastic SyndromesClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials2
- GTB-5550 in Advanced Solid TumorsPHASE1 · RECRUITING · started Apr 8, 2026ClinicalTrials.gov NCT07541573 · fetched Nov 12, 2026
- GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological MalignanciesPHASE1_PHASE2 · TERMINATED · started Jan 1, 2020ClinicalTrials.gov NCT03214666 · fetched Nov 12, 2026
SEC filings12
- S-1 · S-1SEC EDGAR · filed Oct 9, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Sep 25, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Sep 21, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Sep 15, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Sep 3, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 14, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Aug 14, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 12, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 22, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 15, 2026 · fetched Nov 12, 2026
- S-1 · S-1SEC EDGAR · filed Apr 30, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Apr 7, 2026 · fetched Nov 12, 2026